Prana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: ASX:PBT
- CUSIP: N/A
- Web: pranabio.com/
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: -5,010.77%
- Return on Equity: -24.72%
- Return on Assets: -22.71%
Frequently Asked Questions for Prana Biotechnology Limited (ASX:PBT)
What is Prana Biotechnology Limited's stock symbol?
Prana Biotechnology Limited trades on the ASX under the ticker symbol "PBT."
Who are some of Prana Biotechnology Limited's key competitors?
Some companies that are related to Prana Biotechnology Limited include Adelaide Brighton (ABC), AGL Energy Ltd (AGL), AGL Energy Ltd (AGK), Alacer Gold Corp - CDI (AQG), ALS Ltd (ALQ), Alumina Limited (AWC), Amcor Limited (AMC), AMP Limited (AMP), Ansell Limited (ANN), APA Group (APA), Aquarius Platinum Limited (AQP), Ardent Leisure Group (AAD), Aristocrat Leisure Limited (ALL), Arrium Ltd (ARI), Asciano Ltd (AIO), ASX Ltd (ASX), Atlas Iron Limited (AGO) and Augend Ltd (TTN).
Who are Prana Biotechnology Limited's key executives?
MarketBeat Community Rating for Prana Biotechnology Limited (ASX PBT)MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Prana Biotechnology Limited's management team includes the folowing people:
- Geoffrey Paul Kempler, Executive Chairman of the Board, Chief Executive Officer
- Kathryn Andrews, Chief Financial Officer
- Dianne Angus, Chief Operating Officer
- Phillip Hains, Company Secretary
- Ira Shoulson, Non-Executive Director
- Lawrence Gozlan, Non-Executive Independent Director
- Peter Ashley Marks, Non-Executive Independent Director
- Brian Derek Meltzer, Non-Executive Independent Director
- George William Mihaly, Non-Executive Independent Director
Consensus Ratings for Prana Biotechnology Limited (ASX:PBT) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Prana Biotechnology Limited (ASX:PBT)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Prana Biotechnology Limited (ASX:PBT)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Prana Biotechnology Limited (ASX:PBT)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Prana Biotechnology Limited (ASX:PBT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Prana Biotechnology Limited (ASX:PBT)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Prana Biotechnology Limited (ASX:PBT)
Latest Headlines for Prana Biotechnology Limited (ASX:PBT)